Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2018
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in patients with T1D.
Epistemonikos ID: 6afc4e6ea1cd5960b8a9d62f5408a8ad1b2b4666
First added on: Jul 02, 2024